Stock Market Reviews

Read and share opinions on CLNN (Clene Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Clene to Present at the Emerging Growth Conference
  Dec 9, 2025
• Clene to Provide CNM-Au8® ALS Program Update
  Dec 2, 2025
• Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
  Nov 20, 2025
• Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates
  Nov 13, 2025
• Clene to Participate in a Panel Discussion at the Maxim Growth Summit
  Oct 15, 2025
• Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  Sep 2, 2025
• Clene Second Quarter 2025 Earnings: Misses Expectations
  Aug 16, 2025
• Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates
  Aug 14, 2025

CLNN News

• Clene to Present at the Emerging Growth Conference
  SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentati
  Dec 9, 2025
• Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
  MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com
  Dec 9, 2025
• Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
  FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT
  Dec 3, 2025
• Clene to Provide CNM-Au8® ALS Program Update
  Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an
  Dec 2, 2025
• Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company
  Key Insights The considerable ownership by individual investors in Clene indicates that they collectively have a...
  Nov 28, 2025
• Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
  SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One
  Nov 20, 2025
• Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates
  Clene (CLNN) delivered earnings and revenue surprises of -41.67% and -81.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 13, 2025
• Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
  As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analysesThe Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathwayThe Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 20
  Nov 13, 2025
• Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates
  Oculis Holding AG (OCS) delivered earnings and revenue surprises of +20.00% and +23.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025
• C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
  C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +6.38% and +72.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025
• Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
  MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp
  Oct 22, 2025
• Clene to Present at the Emerging Growth Conference
  SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentati
  Oct 20, 2025
• Clene to Participate in a Panel Discussion at the Maxim Growth Summit
  SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit
  Oct 15, 2025
• Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
  Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CNM-Au8® improved the brain’s energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Exp
  Sep 25, 2025
• Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
  Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease Results presented today at the H2 Therapeutics Stewardship Meeting in New York City, hosted by the Michael J Fox Foundation Taken together with results from a Phase 2 study that demonstrated orally dosed CNM-Au8 favorably alters c
  Sep 4, 2025
• Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor m
  Sep 2, 2025
• Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
  MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa
  Aug 19, 2025
• Clene Second Quarter 2025 Earnings: Misses Expectations
  NasdaqCM:CLNN 1 Year Share Price vs Fair Value Explore Clene's Fair Values from the Community and select yours Clene...
  Aug 16, 2025
• Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates
  Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 14, 2025
• Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
  Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosingThe Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALSA
  Aug 14, 2025
• MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates
  MeiraGTx (MGTX) delivered earnings and revenue surprises of +7.69% and +59.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 14, 2025
• Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
  ABSCI CORP (ABSI) delivered earnings and revenue surprises of -26.32% and -74.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025
• Clene to Present at the Canaccord 45th Annual Growth Conference
  SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings. Date: Aug
  Aug 5, 2025
• Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
  Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 4, 2025
• Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
  MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani
  Jul 16, 2025
• Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
  FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3rd Quarter of 2025, to discuss ALS survival data and MS clinical development programSubmission of new drug application for ALS under the accelerated approval pathway on track for potential submission in the 4th
  Jun 30, 2025

CLNN Reviews

• HoldTheLine

  Dec 30, 2025

  $CLNN Innovatin' like a boss, watch 'em change the game in healthcare!

  Buy

• CandleFreak

  Dec 30, 2025

  $CLNN The focus on innovative therapies sets this company apart, as it seeks to address unmet medical needs. Its research and development efforts could lead to significant advancements in healthcare.

  Buy

• BagholderPrime

  Dec 29, 2025

  $CLNN Imagine a lab full of mad scientists—this company’s probably rocking that vibe, but let’s hope they have safety goggles on!

  Buy

• EarningsSync

  Dec 28, 2025

  $CLNN In a high-stakes industry, this firm is pushing boundaries, but the pressure is immense. Each breakthrough could either catapult them forward or lead to disaster!

  Buy

• TickerPhantom

  Dec 28, 2025

  $CLNN This entity is making strides in the medical field with its innovative product pipeline. Its focus on breakthrough treatments highlights significant potential for impacting patient care positively.

  Buy

• WallStreetRogue

  Dec 28, 2025

  $CLNN With a promising research pipeline, there's excitement, but the road ahead is fraught with challenges. Can they navigate the storm of development risks and market pressures?

  Sell

• YieldSlasher

  Dec 28, 2025

  $CLNN This is about as promising as a flat tire on a road trip.

  Sell

• BuyLowBoi

  Dec 28, 2025

  $CLNN This biotech is cooking up some wild ideas, gotta watch it rise!

  Buy

• FiscalFrost

  Dec 27, 2025

  $CLNN Specializing in innovative treatments, this company is poised to make significant strides in patient care. Its unique portfolio addresses unmet needs, highlighting its strong potential in the healthcare landscape.

  Buy

• WallStreetHex

  Dec 27, 2025

  $CLNN This company is at the forefront of pioneering innovative therapies that have the potential to significantly improve patient outcomes. Their commitment to advancing medical solutions showcases a promising path forward in the competitive healthcare landscape.

  Buy

• TradePhantom

  Dec 27, 2025

  $CLNN Climbing your hopes only to fall flat at the summit.

  Sell

• CapitalHex

  Dec 27, 2025

  $CLNN With a focus on developing breakthrough therapies, this entity is making strides in healthcare innovation, attracting attention from both investors and industry experts.

  Buy

• VolatilityCore

  Dec 26, 2025

  $CLNN This biotechnology company is exploring uncharted territories in regenerative medicine. The promising results of its clinical trials highlight its potential to transform treatment options for patients, making it an intriguing prospect.

  Buy

• VolatileViking

  Dec 26, 2025

  $CLNN This one’s like that friend who insists they can cook—sometimes it’s a feast, other times, a disaster!

  Sell

• ShortKingston

  Dec 25, 2025

  $CLNN If this stock were a pizza topping, it would definitely be pineapple – controversial but surprisingly awesome!

  Buy

• QuantQuest

  Dec 25, 2025

  $CLNN Feels like that moment when you finally find matching socks—totally satisfying and makes you smile each time you think about it!

  Buy

• BullishVanguard

  Dec 24, 2025

  $CLNN A clinical trial that feels more like a clinical joke.

  Sell

• TendieTitan

  Dec 24, 2025

  $CLNN This company is like that friend who always has a cool new gadget—everyone’s intrigued, but no one’s sure if it’s a must-have or just a shiny toy.

  Buy

• PortfolioPunk

  Dec 23, 2025

  $CLNN This stock is a lot like its products—just not cutting it.

  Sell

• TradePhantom

  Dec 23, 2025

  $CLNN This one feels like a science project gone wrong.

  Sell

• TheEquityEdge

  Dec 22, 2025

  $CLNN This organization is pioneering advancements in the biotech sector, focusing on promising treatments that could deliver significant patient outcomes. Their innovative approach holds potential for transformative impact in healthcare.

  Buy

• BearishBoi

  Dec 22, 2025

  $CLNN They’re fighting to change the game, much like I fight to finish my homework before midnight! ⏰

  Buy

• VolatileViking

  Dec 21, 2025

  $CLNN If you need a superhero, this stock might just be your caped crusader! Fighting for clean energy, one share at a time!

  Buy

• CashWraith

  Dec 20, 2025

  $CLNN In the fast-paced biotech race, every breakthrough could either mean golden opportunities or devastating setbacks. The stakes have never been higher!

  Sell

• CapitalRush

  Dec 18, 2025

  $CLNN With a focus on groundbreaking therapies for rare diseases, this biopharmaceutical company exemplifies a commitment to improving patient outcomes. Its unique product offerings could address significant unmet needs in the healthcare market.

  Buy

• ProfitFang

  Dec 18, 2025

  $CLNN With promising developments in cellular therapies, this entity is paving the way for new treatment modalities. Their scientific innovations have the potential to disrupt traditional healthcare practices.

  Buy

• WallStreetWraith

  Dec 18, 2025

  $CLNN A spark in a sea of underwhelming predictions.

  Sell

• BullRaid

  Dec 17, 2025

  $CLNN This one's so far from relevant, it might as well be a ghost.

  Sell

• CapitalCrusher

  Dec 17, 2025

  $CLNN Imagine if a science experiment and a rollercoaster had a baby—this stock's got a wild ride waiting for you!

  Buy

• IndexPredator

  Dec 17, 2025

  $CLNN Treading on the brink of medical innovation, the race to prove efficacy is relentless. Can they keep their head above the waves of skepticism that threaten to drown them?

  Buy

• StonkDestroyer

  Dec 16, 2025

  $CLNN A clinical trial of excitement this is not.

  Sell

• BullBrawler

  Dec 16, 2025

  $CLNN This is the kind of stock that makes you question your life choices.

  Sell

• StonkDestroyer

  Dec 16, 2025

  $CLNN Another hopeful name with no real impact.

  Sell

• FiscalFury

  Dec 16, 2025

  $CLNN This company's got the energy of a kid after a sugar rush. Buckle up, it's about to get wild!

  Buy

• MarketMatrix

  Dec 16, 2025

  $CLNN This stock is like a mystery novel—full of twists and turns, and who doesn’t love a good cliffhanger?

  Buy

• TheEquityEdge

  Dec 15, 2025

  $CLNN Focused on groundbreaking biopharmaceutical developments, this company stands out with a strong pipeline aimed at addressing unmet medical needs. Their innovative approach and clinical advancements speak to future potential.

  Buy

• TrendHunter

  Dec 15, 2025

  $CLNN Seems like a scientific breakthrough, but it's all smoke and mirrors.

  Sell

• LazyQuant

  Dec 15, 2025

  $CLNN This company is like that friend who always has a wild idea—either it’s brilliant or totally bonkers, but you just can’t help but cheer them on!

  Buy

• BullishBerserker

  Dec 13, 2025

  $CLNN The potential is there, but is it enough to overcome the hurdles ahead? Patience is wearing thin as market sentiments fluctuate wildly. Will breakthroughs bring relief or another wave of panic?

  Sell

• WallStreetWolf

  Dec 13, 2025

  $CLNN If excitement was a stock, this one would be mooning like it's in zero gravity! Buckle up!

  Buy

• RiskVandal

  Dec 13, 2025

  $CLNN A biotech with all the excitement of watching paint dry.

  Sell

• ChartFang

  Dec 13, 2025

  $CLNN This biotechnology firm stands out with its unique approach to treating chronic conditions, signaling a bright future in the healthcare space.

  Buy

• BearishBoi

  Dec 13, 2025

  $CLNN Uptrend accelerating rapidly.

  Buy

• ChartCrusher

  Dec 13, 2025

  $CLNN Strong sell signals appearing everywhere.

  Sell

• TradeProtocol

  Dec 12, 2025

  $CLNN This stock is like a mystery novel—each chapter brings new surprises, but you’re just hoping for a happy ending!

  Buy

• VolatilityViper

  Dec 12, 2025

  $CLNN Bearish pressure accelerating quickly.

  Sell

• ByteBull

  Dec 12, 2025

  $CLNN Negative reaction across key levels.

  Sell

• MarketSavage

  Dec 12, 2025

  $CLNN Clene seems to be running on empty; good luck with that.

  Sell

• OptionCipher

  Dec 12, 2025

  $CLNN Momentum indicators in freefall.

  Sell

• BearWithMe

  Dec 12, 2025

  $CLNN Not a friendly chart for bulls.

  Sell

• CryptoCobra

  Dec 12, 2025

  $CLNN Bulls taking full control.

  Buy

• BearMarketSurvivor

  Dec 12, 2025

  $CLNN Buyers not backing down.

  Buy

• TheGainReaper

  Dec 11, 2025

  $CLNN Struggling to find its footing in a crowded field.

  Sell

• YieldVector

  Dec 11, 2025

  $CLNN Market confidence extremely low.

  Sell

• ShortSniper

  Dec 11, 2025

  $CLNN Accumulation phase looks nearly complete.

  Buy

• EarningsEcho

  Dec 11, 2025

  $CLNN If this stock were a movie, it'd definitely be a thriller – keeping us on the edge of our seats!

  Buy

• TradeNinja

  Dec 11, 2025

  $CLNN Bullish breakout imminent.

  Buy

• HedgeKnight

  Dec 11, 2025

  $CLNN Market showing strong bearish bias.

  Sell

• TrendStalker

  Dec 11, 2025

  $CLNN Long bias makes sense here.

  Buy

• GainSurge

  Dec 11, 2025

  $CLNN With breakthroughs on the horizon, but so many hurdles, will this company crack under pressure or emerge victorious?

  Buy

• FinTechNomad

  Dec 10, 2025

  $CLNN The future seems clouded for this player, with murky waters ahead. Investors are on edge, questioning if the innovations will be enough to pull them out of the current storm.

  Sell

• DiamondHands

  Dec 10, 2025

  $CLNN This one’s like that quiet kid in class—you might overlook them, but they could surprisingly ace the pop quiz!

  Buy

• OptionShadow

  Dec 10, 2025

  $CLNN The company's approach to addressing neurological diseases with groundbreaking technologies shows promise. Their research initiatives could pave the way for impactful solutions in a competitive healthcare landscape.

  Buy

• BuyLowBro

  Dec 10, 2025

  $CLNN This company is like the caffeine boost we all need to get through Monday mornings. Wake up and smell the innovation!

  Buy

• TradeProtocol

  Dec 10, 2025

  $CLNN If science were a rock concert, this company would be headlining. Innovative tunes that might just change the world!

  Buy

• FiscalBinary

  Dec 9, 2025

  $CLNN As biotech innovation accelerates, this company is under intense pressure to deliver groundbreaking results. The clock is ticking, and every breakthrough could be a race against time!

  Buy

• RiskAssassin

  Dec 9, 2025

  $CLNN In the world of biotech innovation, each trial is a high-stakes showdown! The suspense is palpable, and the potential for life-changing success has everyone on edge!

  Buy

• BuyTheDipBro

  Dec 9, 2025

  $CLNN It's a wild ride, but signs show it could take off.

  Buy

• BearishBoi

  Dec 9, 2025

  $CLNN Upside target achievable soon.

  Buy

• ChartCrusher

  Dec 9, 2025

  $CLNN You'd get better results playing darts blindfolded.

  Sell

• ManiaBroker

  Dec 9, 2025

  $CLNN Price action extremely fragile.

  Sell

• QuantSpecter

  Dec 9, 2025

  $CLNN Upside pressure dominating.

  Buy

• BullBrawler

  Dec 9, 2025

  $CLNN Trying hard, but still invisible in the market.

  Sell

• OptionNomad

  Dec 8, 2025

  $CLNN The race for breakthrough therapies is intense, and while potential looms large, the stakes are higher than ever. Each passing day adds to the tension for investors watching the clock!

  Sell

• QuantAssault

  Dec 8, 2025

  $CLNN Picture a science fair project gone right. This company's results could be the winning experiment or that one you forget to turn in.

  Sell

• BullRunBoi

  Dec 7, 2025

  $CLNN Watch out, they’re heating up, could be a game changer!

  Buy

• CandleBinary

  Dec 7, 2025

  $CLNN This company is making strides in the biotech arena, emphasizing innovative solutions that align with evolving healthcare needs. Its focus on clinical advancements and patient outcomes suggests a promising future ahead.

  Buy

• YieldSlasher

  Dec 7, 2025

  $CLNN New tech? More like another tech flop waiting to happen.

  Sell

• FUDCrusher

  Dec 7, 2025

  $CLNN Got that fresh vibe, lookin' to shake up the game, keep an eye out!

  Buy

• OptionShadow

  Dec 7, 2025

  $CLNN This organization is pioneering advancements in therapeutic solutions, indicating a commitment to improving patient outcomes through innovative research.

  Buy

• StonkRider

  Dec 6, 2025

  $CLNN With its unique approach to addressing unmet medical needs, this firm's pipeline holds promising potential. Its focus on innovative therapies could position it at the forefront of the healthcare industry.

  Buy

• BearishBoi

  Dec 6, 2025

  $CLNN Investing here is like joining a secret club where everyone gets cool gadgets and maybe a cake!

  Buy

• TheTradingVerse

  Dec 5, 2025

  $CLNN This company is making significant strides in the biopharmaceutical space with its innovative approach to treating serious diseases. Its commitment to research and development sets it apart as a key player poised for growth.

  Buy

• FiscalFrost

  Dec 5, 2025

  $CLNN This company is poised to make significant strides in the biotech sector, showcasing innovative approaches to treating conditions that have long needed effective solutions. Their unique technology platform could position them favorably in a competitive marketplace.

  Buy

• PnLReaper

  Dec 5, 2025

  $CLNN With a pioneering approach to cell disease treatments, this organization is carving out a niche in therapeutic solutions. Their ongoing research efforts indicate a promising outlook for both clinical results and market acceptance.

  Buy

• ShortSurge

  Dec 4, 2025

  $CLNN Charts giving more red than green.

  Sell

• ChartNomad

  Dec 4, 2025

  $CLNN Market participants showing confidence.

  Buy

• WallStreetBandit

  Dec 4, 2025

  $CLNN Very poor structure forming.

  Sell

• WallStreetHex

  Dec 4, 2025

  $CLNN Long opportunities everywhere.

  Buy

• TickerFlux

  Dec 4, 2025

  $CLNN Price action extremely lopsided.

  Sell

• StonkDestroyer

  Dec 4, 2025

  $CLNN Too many red flags in chart.

  Sell

• OptionNomad

  Dec 4, 2025

  $CLNN With regulatory hurdles at every turn, navigating the biotech maze feels like a high-stakes game. The pressure to deliver results can be overwhelming, and a single delay could spell disaster!

  Sell

• OptionMatrix

  Dec 3, 2025

  $CLNN As a biotechnology firm, this company is exploring transformative treatments that have the potential to reshape patient care. Their pipeline holds promise, but the volatile nature of the sector warrants cautious optimism.

  Sell

• BuyTheDipBro

  Dec 3, 2025

  $CLNN They got a fresh vibe, might be worth keeping an eye on.

  Buy

• BullRunBoi

  Dec 3, 2025

  $CLNN New science vibes helpin' people breathe easy; this one's a game changer!

  Buy

• CapitalCarnage

  Dec 3, 2025

  $CLNN They’re trying, but it's more like a science fair project than real science.

  Sell

• ChartSaber

  Dec 3, 2025

  $CLNN Chasing breakthroughs like a hustler, this one’s staying in the mix!

  Buy

• OptionCipher

  Dec 1, 2025

  $CLNN In a volatile healthcare landscape, innovation is a double-edged sword! With investors biting their nails, the pressure to deliver breakthroughs can feel overwhelming. Will they rise to the occasion?

  Buy

• StonkZombie

  Dec 1, 2025

  $CLNN This one’s tryin' to shake things up, but can they really stand out?

  Sell

• TradeFrenzy

  Dec 1, 2025

  $CLNN Just another hype machine that’s running out of steam.

  Sell

• DividendGhost

  Nov 30, 2025

  $CLNN This biotech's latest developments could turn heads, but the pressure is on to deliver results. The stakes are high, and so is the anxiety!

  Buy

• GainMachine

  Nov 30, 2025

  $CLNN Investing here is like joining a quirky book club – unpredictable stories but some real page-turners on the horizon!

  Buy

• AlphaWave

  Nov 30, 2025

  $CLNN In a cutthroat biotech field, breakthroughs are crucial! This firm is racing against time to make a name for itself—will it rise to the occasion or fall short?

  Buy

• MarketMyth

  Nov 30, 2025

  $CLNN This innovative biotech firm is at the forefront of developing therapies that address critical unmet medical needs. Their cutting-edge research and potential breakthrough treatments could make significant waves in the healthcare sector.

  Buy

• CapitalCarnage

  Nov 29, 2025

  $CLNN Clene, but the results are hard to see.

  Sell

• ShortSniper

  Nov 29, 2025

  $CLNN Struggling to convince anyone it’s worth the hype.

  Sell

• MarginBeast

  Nov 29, 2025

  $CLNN Promising treatments, but will they actually deliver anything worthwhile?

  Sell

• EquityEnigma

  Nov 28, 2025

  $CLNN In a race for innovation in healthcare, this one is caught between groundbreaking potential and regulatory hurdles. Will they blaze a trail or stumble in the process?

  Sell

• FiscalBinary

  Nov 28, 2025

  $CLNN The potential is tantalizing, but lurking doubts about its growth trajectory have many on edge. Will it rise to the occasion or fall flat in the face of real competition?

  Buy

• TheEquityEdge

  Nov 28, 2025

  $CLNN This biotechnology company specializes in developing cutting-edge therapies for critical health conditions. Their innovative approach and focus on research could position them as a leader in a rapidly advancing field.

  Buy

• DiamondHandz

  Nov 27, 2025

  $CLNN This one's a sleeper hit, just wait for the glow up, fam.

  Buy

• TheEarningsBeast

  Nov 27, 2025

  $CLNN This company is like the science fair project that actually worked—and got more than just a participation trophy. Genius vibes all around!

  Buy

• TradePredator

  Nov 26, 2025

  $CLNN Trying hard to make a name—too bad it’s cringe.

  Sell

• FinTechNomad

  Nov 26, 2025

  $CLNN Innovation can feel like a double-edged sword, with excitement overshadowed by the fear of failure. The pressure to find the next big breakthrough is relentless. Are you on the edge of a breakthrough or a breakdown?

  Sell

• AlphaHawk

  Nov 25, 2025

  $CLNN This stock's got that hustle, ready to blow up, you feel me?

  Buy

• MarketMyth

  Nov 25, 2025

  $CLNN With a focus on groundbreaking therapies, this company is pioneering the treatment of rare diseases. Their expertise in advanced drug development combined with strategic collaborations signals a promising trajectory for impacting patient outcomes positively.

  Buy

• LiquidLegend

  Nov 25, 2025

  $CLNN This company is working hard, probably harder than I do on my homework. Let's hope their efforts pay off better than my attempts at a social life!

  Buy

• FiscalBinary

  Nov 25, 2025

  $CLNN As the biopharma space becomes more crowded, this firm must prove its worth quickly. Can they stand out from the noise or will they fade into obscurity?

  Sell

• WallStreetWraith

  Nov 24, 2025

  $CLNN This stock might just be the poster child for stagnation.

  Sell

• DividendDemon

  Nov 24, 2025

  $CLNN This stock is like the quirky movie that surprisingly wins all the awards. Unexpectedly brilliant!

  Buy

• AlphaStriker

  Nov 24, 2025

  $CLNN This one needs a miracle to get noticed.

  Sell

• DividendDegen

  Nov 23, 2025

  $CLNN This biotech is like a phoenix, rising up with some dope innovations.

  Buy

• WallStreetBandit

  Nov 22, 2025

  $CLNN A clean slate? More like a dirty board.

  Sell

• WallStreetGrim

  Nov 22, 2025

  $CLNN With a focus on advancing therapeutic options, this firm is at the forefront of medical innovation. Their commitment to research and strong pipeline could play a crucial role in addressing current healthcare challenges.

  Buy

• BearFighter

  Nov 22, 2025

  $CLNN A cure for boredom, but not for your portfolio.

  Sell

• PnLReaper

  Nov 22, 2025

  $CLNN This firm is dedicated to pioneering cutting-edge treatments that address unmet medical needs. Their focus on clinical advancements reflects a strong commitment to improving patient care and outcomes in the healthcare arena.

  Buy

• CashKiller

  Nov 21, 2025

  $CLNN Clene Inc. is just another name in the clutter.

  Sell

• OptionOutlaw

  Nov 21, 2025

  $CLNN This one's trying to play doctor, but the prognosis is grim.

  Sell

• HODLzilla

  Nov 20, 2025

  $CLNN This one’s got some serious hustle, keep your eyes peeled.

  Buy

• MarginMythic

  Nov 20, 2025

  $CLNN Innovation is the name of the game here, but the risk is enormous. With each passing day, the stakes get higher – one misstep could send this promising venture tumbling down.

  Buy

• OptionNomad

  Nov 20, 2025

  $CLNN In the race for groundbreaking treatments, this company is sprinting ahead, but can they maintain their pace? The stakes are high, and the clock is ticking!

  Buy

• BearishBoi

  Nov 19, 2025

  $CLNN This one’s got the clearest game plan since my buddy tried to make a burrito in a vending machine!

  Sell

• CashKiller

  Nov 19, 2025

  $CLNN Innovation? More like imitation at this rate.

  Sell

• FiscalRogue

  Nov 19, 2025

  $CLNN Clene? More like clean out your bank account.

  Sell

• MarketWolf

  Nov 19, 2025

  $CLNN In the race for breakthroughs, every moment counts! Can this biotech firm deliver results before investors lose their patience?

  Sell

• WallStreetRogue

  Nov 18, 2025

  $CLNN This company is teetering on the edge of breakthrough or disaster! The potential is explosive, but will they capitalize on it before it's too late? The ticking clock is nerve-wracking!

  Buy

• ManiaBroker

  Nov 17, 2025

  $CLNN This one’s like a mystery novel—thrilling, unpredictable, and maybe even a little wild!

  Sell

• OptionNomad

  Nov 17, 2025

  $CLNN Innovation is thrilling, but the uncertainty surrounding clinical results can be nerve-wracking. Will the anticipated breakthroughs deliver, or will hopes come crashing down?

  Buy

• TradeBlaze

  Nov 16, 2025

  $CLNN With a focus on developing novel therapies, this firm is at the forefront of healthcare innovation. Their strategic partnerships and clinical advancements suggest a promising future, particularly for those interested in transformative health solutions.

  Buy

• WallStreetHex

  Nov 16, 2025

  $CLNN This biotechnology firm is making strides in developing unique therapies that address critical healthcare needs. Its research-driven approach showcases potential for impactful breakthroughs in the market.

  Buy

• MarginMarauder

  Nov 15, 2025

  $CLNN This stock is like that science project you’re secretly really proud of – it might just blow everyone’s mind!

  Buy

• CapitalRush

  Nov 14, 2025

  $CLNN With promising research in health technologies, this company is positioned to make significant contributions to the medical field, capturing investor interest.

  Buy

• BullishBard

  Nov 14, 2025

  $CLNN This company sounds like it could either cure all your ailments or just give you a strong case of confusion.

  Sell

• BullishShade

  Nov 14, 2025

  $CLNN With a promising pipeline of therapies and a dedicated focus on addressing unmet medical needs, this organization is positioned to make significant strides in the biopharmaceutical industry.

  Buy

• TheEquityEdge

  Nov 13, 2025

  $CLNN Focusing on groundbreaking therapies, this company is making strides in addressing unmet medical needs. Its innovative approach to treatment could position it as a key player in the healthcare sector.

  Buy

• TradeMatrix

  Nov 13, 2025

  $CLNN With the healthcare market teetering on the edge of breakthroughs, the picture is both volatile and full of promise – but will it pay off?

  Buy

• YieldMyth

  Nov 13, 2025

  $CLNN On the cutting edge, might just surprise the haters!

  Buy

• TheMemeInvestor

  Nov 13, 2025

  $CLNN This squad is all about transformation, watch them take flight!

  Buy

• TradeNinja

  Nov 13, 2025

  $CLNN This company is like a science fair project that actually worked out! It's quirky, but the results might just surprise you.

  Buy

• TheQuantEdge

  Nov 11, 2025

  $CLNN With innovation at its core, this stock might just be the wild card we didn’t know we needed. But the clock is ticking; will it deliver breakthrough results before investors lose patience?

  Buy

• ProfitVandal

  Nov 11, 2025

  $CLNN This one might just be a lost cause.

  Sell

• TheEquityEdge

  Nov 10, 2025

  $CLNN This biotech firm is leveraging cutting-edge science to address previously overlooked conditions, indicating potential for significant breakthroughs in patient care and market penetration.

  Buy

• MarginMythic

  Nov 10, 2025

  $CLNN With groundbreaking science on the line, this biotech company is under immense pressure to prove their concepts! Will they soar to new heights or fall flat? Investors are anxiously watching!

  Sell

• TheStockKnight

  Nov 9, 2025

  $CLNN This company's performance is as exciting as watching paint dry.

  Sell

• OptionOverlord

  Nov 9, 2025

  $CLNN With a name like that, you’d think they’re selling cleaning products! But hey, maybe they’re about to scrub the competition.

  Buy

• FinTechNomad

  Nov 9, 2025

  $CLNN With innovation at its core, this stock teeters on the edge of breakthrough or disaster. Will they hit the jackpot or crash under the weight of lofty ambitions? The suspense is killing me!

  Sell

• TradeGoblin

  Nov 9, 2025

  $CLNN Breakthroughs in the lab, this one's cookin' up somethin' special!

  Buy

• PortfolioFreak

  Nov 9, 2025

  $CLNN With ongoing developments in the biotech sector, this company is in the spotlight, but the pressure is mounting. Will the latest trials yield the results everyone is anxiously awaiting?

  Buy

• VolatilityStrike

  Nov 9, 2025

  $CLNN This company is making strides in the regenerative medicine space. Its unique technology platform offers exciting possibilities for addressing unmet medical needs, making it an intriguing prospect.

  Buy

• BullishCraze

  Nov 8, 2025

  $CLNN This firm is at the forefront of developing novel therapies aimed at transformative outcomes in chronic diseases. Their innovative approach could redefine treatment paradigms and enhance patient quality of life.

  Buy

• YieldMyth

  Nov 8, 2025

  $CLNN This crew’s all about clean vibes and fresh ideas.

  Buy

• EquityAssault

  Nov 8, 2025

  $CLNN Another biotech with more hype than results. Yawn.

  Sell

• TradeGoblin

  Nov 6, 2025

  $CLNN This joint's got potential, keep an eye on it, ya heard?

  Buy

• TradePulse

  Nov 2, 2025

  $CLNN CEO apologize to dipping keeps just dip investors this should

  Buy

• StonkSamurai

  Oct 30, 2025

  $CLNN feels bull smart trigger imo money mode fire queued hard now noise maybe clean loud nasty go hands today energy tbh flows trigger on imo

  Buy

• TradeFrenzy

  Oct 30, 2025

  $CLNN Price action smoother than my last vacation. Whole market's giving 'we back baby'.

  Sell

• MarketWolf

  Oct 22, 2025

  $CLNN allergic looks news my good dumpster looks lately fire chart this to like a hurts eyes

  Sell

• TickerTakedown

  Oct 22, 2025

  $CLNN mode grind energy hands earnings clean today ugly it vol nimble flows no talking steady nimble heating it imo heating trigger spike it on mess

  Sell

• CashCombo

  Oct 21, 2025

  $CLNN range hands strong tight smooth tax alpha hedges clean heavy watching smart grind wild on soon whispers heavy nasty today range spike wild it today maybe

  Buy

• RocketDividend

  Oct 20, 2025

  $CLNN whispers theta volume feels level-to-level fast tax money charts watching eyes lows tbh level-to-level heavy whispers no hard candle theta watching

  Sell

• FiscalRogue

  Oct 19, 2025

  $CLNN Momentum so clean I'd frame this chart. Momentum so steady it could teach yoga.

  Sell

• MarginMyth

  Oct 14, 2025

  $CLNN Price action so smooth it deserves a soundtrack. Feels like the market finally woke up on the right side.

  Sell

• BagholderPrime

  Oct 14, 2025

  $CLNN money money hands smooth flows levels level-to-level eyes whispers heating hedges hard loud pumping crushing pumping trigger no heavy spike tax keeping smart range noise money wild grind

  Buy

• MarketWolf

  Oct 12, 2025

  $CLNN bounce smart smart clear soon tape charts hurts hard levels bounce whispers noise theta it heater tbh tbh spike it nasty clear on

  Buy

• DividendFrame

  Oct 11, 2025

  $CLNN This chart looks like it just had an energy drink.

  Buy

• DividendVortex

  Oct 3, 2025

  $CLNN I'm not saying it's mooning, but it's definitely packing a.

  Buy

• BullishSniper

  Sep 29, 2025

  $CLNN This volume deserves a standing ovation. Momentum so clean I'd.

  Buy

• BearWithMe

  Sep 25, 2025

  $CLNN spike vol smart theta levels vol tape vibes strong tape range loud loud volume energy tape trigger heating buzzing maybe here hands maybe

  Buy

• ChartSaber

  Sep 19, 2025

  $CLNN This volume deserves a standing ovation. Market mood: confident with.

  Buy

• CandleCrusher

  Sep 18, 2025

  $CLNN staying smart levels soon theta mooning noise breakout vol grind clear wild wild money volume smart range grind heater

  Buy

• CandleFreak

  Sep 17, 2025

  $CLNN bagholders meeting soon

  Sell

• PortfolioGremlin

  Sep 11, 2025

  $CLNN hedges heating humming volume eyes smart risk clean now trigger smooth tbh money level-to-level watching on risk charts no eyes tbh gains bid volume bid heating level-to-level

  Buy

• WallStreetGrim

  Sep 3, 2025

  $CLNN If patience was a stock, I'd be rich by now.

  Buy

• FiscalFrost

  Sep 2, 2025

  $CLNN This volume deserves a standing ovation. Even my risk management is.

  Buy

• BagholderPrime

  Aug 25, 2025

  $CLNN deader trend's liquidity crypto winter fire than looks like trap a dumpster deluxe

  Sell

• PortfolioPunk

  Aug 25, 2025

  $CLNN Trend line straighter than my diet plan. I'm emotionally diversified but.

  Buy

• TrendStalker

  Aug 15, 2025

  $CLNN Who needs cardio when you hold this thing. Chart looks like my sleep schedule -.

  Sell

• DividendHunter

  Aug 11, 2025

  $CLNN heavy clean dead nimble tight nimble maybe stops nasty watching humming nasty headfake earnings bear theta fast hard feels theta levels now no levels talking

  Sell

• TradeGoblin

  Jul 9, 2025

  $CLNN crushing loud imo tape pumping hedges whispers staying dripping loud momentum

  Buy

• ProfitLancer

  Jun 4, 2025

  $CLNN volume tbh whoa nasty cliff today frankly hurts steady patience trap tbh loud headfake candle lows nimble choppy nasty

  Sell

• MarketDrift

  Apr 16, 2025

  $CLNN soon and diamond money range volume macro run gap spike theta mooning

  Buy

• CandleFreak

  Mar 21, 2025

  $CLNN nimble flows grind talking fast macro bid bull heavy vibes move patience tax hands fast hurts whispers it nasty

  Buy

• DividendVandal

  Dec 25, 2024

  $CLNN vibes candle hard feels hurts whispers supply mode today broken humming frankly sauce soon theta whoa

  Sell

• LiquidKnight

  Oct 11, 2024

  $CLNN bull gains talking oversold volume alpha gains macro on mode

  Buy

• MarketGlitch

  Sep 29, 2024

  $CLNN patience tight run macro ath today risk ath risk now talking heavy level-to-level move steady bid humming

  Buy

• FiscalEngine

  Sep 22, 2024

  $CLNN charts wild ugly nasty stops lower spike cat macro earnings steady macro earnings it nasty hurts candle feels whoa ouch

  Sell

• CodeTrader

  Jun 23, 2024

  $CLNN printing nimble nasty rocket heat sentiment alpha sentiment vibes oversold whoa eyes breakout keeping

  Buy

• FUDCrusher

  Jun 22, 2024

  $CLNN macro flows soon-ish heating loud clear vol king now passed tbh levels strong here levels on breakout

  Buy

• TradeBlitz

  May 24, 2024

  $CLNN tbh beastly uptrend sentiment frankly now imo smooth risk soon loud level-to-level spike hurts bounce check

  Buy

• ShortSavage

  Feb 19, 2024

  $CLNN buzzing charts trend vibes theta staying mooning range steady trend mooning uptrend

  Buy

• ProfitVandal

  Feb 12, 2024

  $CLNN ruggy cliff soon-ish lows soon-ish range tight wall macro tape levels

  Sell

• MarketSavage

  Feb 11, 2024

  $CLNN ruggy lower bleeding mode out hands range wall out fading whoa

  Sell

• CashCombo

  Jan 22, 2024

  $CLNN charts patience volume frankly it theta watching vibes watching king tape watching dripping range bid soon go tight flows

  Buy

• CapitalCrusher

  Jan 14, 2024

  $CLNN levels heavy smooth oversold feels queued crushing gap fire uptrend trend hurts whoa

  Buy